Structural and Functional Remodeling of the Left Atrium. Clinical and Therapeutic Implications for Atrial Fibrillation

Journal of the American College of Cardiology

Volumn 51, Issue 1, 2008, Pages 1-11

  Casaclang Verzosa, Grace ^a   Gersh, Bernard J ^a   Tsang, Teresa S M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALAGEBRIUM; ALDOSTERONE ANTAGONIST; AMILORIDE; AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; METOPROLOL; OMAPATRILAT; PIRFENIDONE; PLACEBO; QUINAPRIL; SIMVASTATIN; SPIRONOLACTONE; TRANDOLAPRIL; TRANSFORMING GROWTH FACTOR BETA; VALSARTAN;

AGING; BIOMECHANICS; CARDIOVERSION; CLINICAL TRIAL; DIASTOLIC HEART FAILURE; DRUG EFFECT; DRUG MECHANISM; EPIDEMIC; HEART ATRIUM FIBRILLATION; HEART ATRIUM FUNCTION; HEART FAILURE; HEART LEFT ATRIUM; HEART MUSCLE METABOLISM; HEART SURGERY; HUMAN; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SYSTEMIC DISEASE; TACHYCARDIA; TISSUE REPAIR; TREATMENT OUTCOME;

AGING; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIFIBRINOLYTIC AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; CLINICAL TRIALS AS TOPIC; ELECTRIC COUNTERSHOCK; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HEART ATRIA; HUMANS;

EID: 37449009956     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.09.026     Document Type: Review

References (171)

1. Abhayaratna W.P., Seward J.B., Appleton C.P., et al. Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol 47 (2006) 2357-2363
2. Nattel S. Electrophysiologic remodeling: are ion channels static players or dynamic movers?. J Cardiovasc Electrophysiol 10 (1999) 1553-1556
3. Goette A., Honeycutt C., and Langberg J.J. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation 94 (1996) 2968-2974
4. Ausma J., Litjens N., Lenders M.H., et al. Time course of atrial fibrillation-induced cellular structural remodeling in atria of the goat. J Mol Cell Cardiol 33 (2001) 2083-2094
5. Li D.S., Fareh S., Leung T.K., and Nattel S. Promotion of atrial fibrillation by heart failure in dogs-atrial remodeling of a different sort. Circulation 100 (1999) 87-95
6. Colucci W.S., and Braunwald E. Pathophysiology of heart failure. In: Zipes D., Libby P., Bonow R.O., and Braunwald E. (Eds). Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 7th edition (2005), W.B. Saunders, Philadelphia, PA 509-538
7. Hoit B.D., Shao Y., Gabel M., and Walsh R.A. Left atrial mechanical and biochemical adaptation to pacing induced heart failure. Cardiovasc Res 29 (1995) 469-474
8. Hoit B.D., Shao Y., and Gabel M. Left atrial systolic and diastolic function accompanying chronic rapid pacing-induced atrial failure. Am J Physiol 275 (1998) H183-H189
9. Khan A., Moe G.W., Nili N., et al. The cardiac atria are chambers of active remodeling and dynamic collagen turnover during evolving heart failure. J Am Coll Cardiol 43 (2004) 68-76
10. Boixel C., Fontaine V., Rucker-Martin C., et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol 42 (2003) 336-344
11. Ausma J., Wijffels M., Thone F., Wouters L., Allessie M., and Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 96 (1997) 3157-3163
12. Thijssen V.L., Ausma J., Liu G.S., Allessie M.A., van Eys G.J., and Borgers M. Structural changes of atrial myocardium during chronic atrial fibrillation. Cardiovasc Pathol 9 (2000) 17-28
13. Schoonderwoerd B.A., Van Gelder I.C., Van Veldhuisen D.J., Van den Berg M.P., and Crijns H.J. Electrical and structural remodeling: role in the genesis and maintenance of atrial fibrillation. Prog Cardiovasc Dis 48 (2005) 153-168
14. Everett IV T.H., Li H., Mangrum J.M., et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation 102 (2000) 1454-1460
15. Everett IV T.H., Wilson E.E., Verheule S., Guerra J.M., Foreman S., and Olgin J.E. Structural atrial remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a comparison in canine models of structural and electrical atrial remodeling. Am J Physiol Heart Circ Physiol 291 (2006) H2911-H2923
16. Stambler B.S., Fenelon G., Shepard R.K., Clemo H.F., and Guiraudon C.M. Characterization of sustained atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure. J Cardiovasc Electrophysiol 14 (2003) 499-507
17. Li D., Melnyk P., Feng J., et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 101 (2000) 2631-2638
18. Solti F., Vecsey T., Kekesi V., and Juhasz-Nagy A. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res 23 (1989) 882-886
19. Morillo C.A., Klein G.J., Jones D.L., and Guiraudon C.M. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 91 (1995) 1588-1595
20. Shi Y., Ducharme A., Li D., Gaspo R., Nattel S., and Tardif J.C. Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res 52 (2001) 217-225
21. Mary-Rabine L., Albert A., Pham T.D., et al. The relationship of human atrial cellular electrophysiology to clinical function and ultrastructure. Circ Res 52 (1983) 188-199
22. Sinno H., Derakhchan K., Libersan D., Merhi Y., Leung T.K., and Nattel S. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 107 (2003) 1930-1936
23. Kumagai K., Nakashima H., Urata H., Gondo N., Arakawa K., and Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 41 (2003) 2197-2204
24. Cha Y.-M., Dzeja P.P., Shen W.K., et al. Failing atrial myocardium: energetic deficits accompany structural remodeling and electrical instability. Am J Physiol Heart Circ Physiol 284 (2003) H1313-H1320
25. Barger P.M., and Kelly D.P. Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. Am J Med Sci 318 (1999) 36-42
26. Allard M.F., Schonekess B.O., Henning S.L., English D.R., and Lopaschuk G.D. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol Heart Circ Physiol 267 (1994) H742-H750
27. Ausma J., Coumans W.A., Duimel H., Van der Vusse G.J., Allessie M.A., and Borgers M. Atrial high energy phosphate content and mitochondrial enzyme activity during chronic atrial fibrillation. Cardiovasc Res 47 (2000) 788-796
28. Houser S.R., Piacentino III V., and Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 32 (2000) 1595-1607
29. 2+ channel alpha 1c subunit isoform switching in failing human ventricular myocardium. J Mol Cell Cardiol 32 (2000) 973-984
30. Nattel S. Driver regions in atrial fibrillation associated with congestive heart failure: where are they, and what are they telling us?. J Cardiovasc Electrophysiol 16 (2005) 1359-1361
31. Stanley W.C., Lopaschuk G.D., Hall J.L., and McCormack J.G. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 33 (1997) 243-257
32. Dietz J.R. Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc Res 68 (2005) 8-17
33. Tsioufis C., Stougiannos P., Taxiarchou E., et al. The interplay between haemodynamic load, brain natriuretic peptide and left atrial size in the early stages of essential hypertension. J Hypertens 24 (2006) 965-972
34. Hanna N., Cardin S., Leung T.K., and Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 63 (2004) 236-244
35. Miyauchi Y., Zhou S., Okuyama Y., et al. Altered atrial electrical restitution and heterogeneous sympathetic hyperinnervation in hearts with chronic left ventricular myocardial infarction: implications for atrial fibrillation. Circulation 108 (2003) 360-366
36. White M., Rouleau J.L., Hall C., et al. Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction. Am Heart J 142 (2001) 1056-1064
37. Yan R.T., White M., Yan A.T., et al. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol 96 (2005) 698-704
38. Franco V., Chen Y.F., Oparil S., et al. Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling. Hypertension 44 (2004) 746-750
39. Hayashi M., Tsutamoto T., Wada A., et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 37 (2001) 1820-1826
40. Sadoshima J., Xu Y., Slayter H.S., and Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75 (1993) 977-984
41. Yoshihara F., Nishikimi T., Sasako Y., et al. Plasma atrial natriuretic peptide concentration inversely correlates with left atrial collagen volume fraction in patients with atrial fibrillation: plasma ANP as a possible biochemical marker to predict the outcome of the MAZE procedure. J Am Coll Cardiol 39 (2002) 288-294
42. Wozakowska-Kaplon B., and Opolski G. Atrial natriuretic peptide level after cardioversion of chronic atrial fibrillation. Int J Cardiol 83 (2002) 159-165
43. van den Berg M.P., Tjeerdsma G., Jan de Kam P., Boomsma F., Crijns H.J., and van Veldhuisen D.J. Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced congestive heart failure. Eur J Heart Fail 4 (2002) 255-262
44. Lim T.K., Ashrafian H., Dwivedi G., Collinson P.O., and Senior R. Increased left atrial volume index is an independent predictor of raised serum natriuretic peptide in patients with suspected heart failure but normal left ventricular ejection fraction: implication for diagnosis of diastolic heart failure. Eur J Heart Fail 8 (2006) 38-45
45. Barclay J.L., Kruszewski K., Croal B.L., Cuthbertson B.H., Oh J.K., and Hillis G.S. Relation of left atrial volume to B-type natriuretic peptide levels in patients with stable chronic heart failure. Am J Cardiol 98 (2006) 98-101
46. Detaint D., Messika-Zeitoun D., Avierinos J.F., et al. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation 111 (2005) 2391-2397
47. Arima M., Kanoh T., Kawano Y., Oigawa T., Yamagami S., and Matsuda S. Plasma levels of brain natriuretic peptide increase in patients with idiopathic bilateral atrial dilatation. Cardiology 97 (2002) 12-17
48. Inoue S., Murakami Y., Sano K., Katoh H., and Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 6 (2000) 92-96
49. Kim B.J., Hwang S.J., Sung K.C., et al. Assessment of factors affecting plasma BNP levels in patients with chronic atrial fibrillation and preserved left ventricular systolic function. Int J Cardiol 118 (2007) 145-150
50. Morello A., Lloyd-Jones D.M., Chae C.U., et al. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am Heart J 153 (2007) 90-97
51. Corell P., Gustafsson F., Kistorp C., Madsen L.H., Schou M., and Hildebrandt P. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure. Int J Cardiol 117 (2007) 395-402
52. Osranek M., Fatema K., Qaddoura F., et al. Left atrial volume predicts the risk of atrial fibrillation after cardiac surgery: a prospective study. J Am Coll Cardiol 48 (2006) 779-786
53. Wazni O.M., Martin D.O., Marrouche N.F., et al. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 110 (2004) 124-127
54. Weber K.T., Brilla C.G., Campbell S.E., Guarda E., Zhou G., and Sriram K. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol 88 Suppl 1 (1993) 107-124
55. Brilla C.G., Maisch B., and Weber K.T. Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation. Clin Invest 71 (1993) S35-S41
56. Brilla C.G., Matsubara L.S., and Weber K.T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 25 (1993) 563-575
57. 1. Circ Res 94 (2004) 1498-65
58. 1 signaling in ventricular cardiomyocytes of rat. J Mol Med 84 (2006) 975-983
59. Nabah Y.N., Mateo T., Estelles R., et al. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 110 (2004) 3581-3586
60. Usui M., Egashira K., Tomita H., et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 101 (2000) 305-310
61. Brown N.J., and Vaughan D.E. Prothrombotic effects of angiotensin. Adv Intern Med 45 (2000) 419-429
62. Pawlak R., Chabielska E., Matys T., Kucharewicz I., Rolkowski R., and Buczko W. Thiol repletion prevents venous thrombosis in rats by nitric oxide/prostacyclin-dependent mechanism: relation to the antithrombotic action of captopril. J Cardiovasc Pharmacol 36 (2000) 503-509
63. Pawlak R., Chabielska E., Golatowski J., Azzadin A., and Buczko W. Nitric oxide and prostacyclin are involved in antithrombotic action of captopril in venous thrombosis in rats. Thromb Haemost 79 (1998) 1208-1212
64. Goette A., Staack T., Rocken C., et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 35 (2000) 1669-1677
65. Khan R., and Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-1 in cardiomyopathy, valvular disease and arrhythmia. Immunology 118 (2006) 10-24
66. Stockand J.D., and Meszaros J.G. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol 284 (2003) H176-H184
67. Rude M.K., Duhaney T.-A.S., Kuster G.M., et al. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension 46 (2005) 555-561
68. Thai H., Castellano L., Juneman E., et al. Pretreatment with angiotensin receptor blockade prevents left ventricular dysfunction and blunts left ventricular remodeling associated with acute myocardial infarction. Circulation 114 (2006) 1933-1939
69. Wong G.C., Marcotte F., and Rudski L.G. Impact of chronic lisinopril therapy on left atrial volume versus dimension in chronic organic mitral regurgitation. Can J Cardiol 22 (2006) 125-129
70. Madrid A.H., Peng J., Zamora J., et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 27 (2004) 1405-1410
71. Shroff S.C., Ryu K., Martovitz N.L., Hoit B.D., and Stambler B.S. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 17 (2006) 534-541
72. Anne W., Willems R., Roskams T., et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc Res 67 (2005) 655-666
73. Boldt A., Wetzel U., Weigl J., et al. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 42 (2003) 1785-1792
74. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo M.A., and Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96 (1997) 1180-1184
75. Psychari S.N., Apostolou T.S., Sinos L., Hamodraka E., Liakos G., and Kremastinos D.T. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 95 (2005) 764-767
76. Chung M.K., Martin D.O., Sprecher D., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104 (2001) 2886-2891
77. Watanabe T., Takeishi Y., Hirono O., et al. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels 20 (2005) 45-49
78. Aviles R.J., Martin D.O., Apperson-Hansen C., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 108 (2003) 3006-3010
79. Malouf J.F., Kanagala R., Al Atawi F.O., et al. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 46 (2005) 1284-1287
80. Dernellis J., and Panaretou M. Left atrial function in patients with a high C-reactive protein level and paroxysmal atrial fibrillation. Acta Cardiol 61 (2006) 507-511
81. Kotur-Stevuljevic J., Memon L., Stefanovic A., et al. Correlation of oxidative stress parameters and inflammatory markers in coronary artery disease patients. Clin Biochem 40 (2007) 181-187
82. Fujii H., Li S.H., Szmitko P.E., Fedak P.W., and Verma S. C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler Thromb Vasc Biol 26 (2006) 2476-2482
83. Winrow V.R., Winyard P.G., Morris C.J., and Blake D.R. Free radicals in inflammation: second messengers and mediators of tissue destruction. Br Med Bull 49 (1993) 506-522
84. Galis Z.S., Asanuma K., Godin D., and Meng X. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy?. Circulation 97 (1998) 2445-2453
85. Fu X., Kassim S.Y., Parks W.C., and Heinecke J.W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 276 (2001) 41279-41287
86. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., and Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 98 (1996) 2572-2579
87. Fedak P.W., Smookler D.S., Kassiri Z., et al. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 110 (2004) 2401-2409
88. Sundstrom J., Evans J.C., Benjamin E.J., et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J 25 (2004) 1509-1516
89. Xu J., Cui G., Esmailian F., et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109 (2004) 363-368
90. Zhong Y., Li S.H., Liu S.M., et al. C-reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 48 (2006) 504-511
91. Zieman S., and Kass D. Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease. Congest Heart Fail 10 (2004) 144-149
92. Little W.C., Zile M.R., Kitzman D.W., Hundley W.G., O'Brien T.X., and Degroof R.C. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11 (2005) 191-195
93. Redfield M.M., Jacobsen S.J., Borlaug B.A., Rodeheffer R.J., and Kass D.A. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation 112 (2005) 2254-2262
94. Redfield M.M. Treating diastolic heart failure with AGE crosslink breakers: thinking outside the heart failure box. J Card Fail 11 (2005) 196-199
95. Aronson D. Pharmacological prevention of cardiovascular aging-targeting the Maillard reaction. Br J Pharmacol 142 (2004) 1055-1058
96. Zieman S.J., Melenovsky V., and Kass D.A. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 25 (2005) 932-943
97. Zieman S.J., and Kass D.A. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 64 (2004) 459-470
98. Kitzman D.W., and Edwards W.D. Age-related changes in the anatomy of the normal human heart. J Gerontol 45 (1990) M33-M39
99. Thomas L., Levett K., Boyd A., Leung D.Y., Schiller N.B., and Ross D.L. Compensatory changes in atrial volumes with normal aging: is atrial enlargement inevitable?. J Am Coll Cardiol 40 (2002) 1630-1635
100. Thomas L., Levett K., Boyd A., Leung D.Y., Schiller N.B., and Ross D.L. Changes in regional left atrial function with aging: evaluation by Doppler tissue imaging. Eur J Echocardiogr 4 (2003) 92-100
101. Nikitin N.P., Witte K.K., Thackray S.D., Goodge L.J., Clark A.L., and Cleland J.G. Effect of age and sex on left atrial morphology and function. Eur J Echocardiogr 4 (2003) 36-42
102. Triposkiadis F., Tentolouris K., Androulakis A., et al. Left atrial mechanical function in the healthy elderly: new insights from a combined assessment of changes in atrial volume and transmitral flow velocity. J Am Soc Echocardiogr 8 (1995) 801-809
103. O'Rourke M.F., and Nichols W.W. Aortic diameter, aortic stiffness, and wave reflection increase with age and isolated systolic hypertension. Hypertension 45 (2005) 652-658
104. Klein A.L., Burstow D.J., Tajik A.J., Zachariah P.K., Bailey K.R., and Seward J.B. Effects of age on left ventricular dimensions and filling dynamics in 117 normal persons. Mayo Clin Proc 69 (1994) 212-224
105. Gottdiener J.S., Kitzman D.W., Aurigemma G.P., Arnold A.M., and Manolio T.A. Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons ≥65 years of age (the cardiovascular health study). Am J Cardiol 97 (2006) 83-89
106. Anyukhovsky E.P., Sosunov E.A., Chandra P., et al. Age-associated changes in electrophysiologic remodeling: a potential contributor to initiation of atrial fibrillation. Cardiovasc Res 66 (2005) 353-363
107. Kistler P.M., Sanders P., Fynn S.P., et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am Coll Cardiol 44 (2004) 109-116
108. Sutton-Tyrrell K., Najjar S.S., Boudreau R.M., et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 111 (2005) 3384-3390
109. Hayashi H., Wang C., Miyauchi Y., et al. Aging-related increase to inducible atrial fibrillation in the rat model. J Cardiovasc Electrophysiol 13 (2002) 801-808
110. Tsang T.S., Barnes M.E., Gersh B.J., Bailey K.R., and Seward J.B. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 90 (2002) 1284-1289
111. Peterson L.R., Waggoner A.D., de las Fuentes L., et al. Alterations in left ventricular structure and function in type-1 diabetics: a focus on left atrial contribution to function. J Am Soc Echocardiogr 19 (2006) 749-755
112. Sasson Z., Rasooly Y., Gupta R., and Rasooly I. Left atrial enlargement in healthy obese: prevalence and relation to left ventricular mass and diastolic function. Can J Cardiol 12 (1996) 257-263
113. Wang T.J., Parise H., Levy D., et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 292 (2004) 2471-2477
114. Nakashima H., Kumagai K., Urata H., Gondo N., Ideishi M., and Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 101 (2000) 2612-2617
115. Abhayaratna W.P., Barnes M.E., Langins A.P., et al. Reversal of left atrial remodeling in patients with "isolated" left ventricular diastolic dysfunction. J Am Coll Cardiol 49 Suppl A (2007) 91A (abstr)
116. Tsang T.S., Barnes M.E., Abhayaratna W.P., et al. Effects of quinapril on left atrial structural remodeling and arterial stiffness. Am J Cardiol 97 (2006) 916-920
117. Hagens V.E., Van Veldhuisen D.J., Kamp O., et al. Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. Heart Rhythm 2 (2005) 19-24
118. Reant P., Lafitte S., Jais P., et al. Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. Circulation 112 (2005) 2896-2903
119. Manning W.J., and Silverman D.I. Atrial anatomy and function postcardioversion: insights from transthoracic and transesophageal echocardiography. Prog Cardiovasc Dis 39 (1996) 33-46
120. Westenberg J.J., van der Geest R.J., Lamb H.J., et al. MRI to evaluate left atrial and ventricular reverse remodeling after restrictive mitral annuloplasty in dilated cardiomyopathy. Circulation 112 (2005) I437-I442
121. Cha Y.-M., Dzeja P.P., Redfield M.M., Shen W.K., and Terzic A. Bioenergetic protection of failing atrial and ventricular myocardium by vasopeptidase inhibitor omapatrilat. Am J Physiol Heart Circ Physiol 290 (2006) H1686-H1692
122. Hornero F., Rodriguez I., Buendia J., et al. Atrial remodeling after mitral valve surgery in patients with permanent atrial fibrillation. J Card Surg 19 (2004) 376-382
123. Lee K.W., Everett T.Ht., Rahmutula D., et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 114 (2006) 1703-1712
124. Li Y., Li W., Yang B., et al. Effects of cilazapril on atrial electrical, structural and functional remodeling in atrial fibrillation dogs. J Electrocardiol 40 (2007) 100.e1-6
125. Milliez P., DeAngelis N., Rucker-Martin C., et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 26 (2005) 2193-2199
126. Shi Y., Li D., Tardif J.C., and Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 54 (2002) 456-461
127. Tops L.F., Bax J.J., Zeppenfeld K., Jongbloed M.R., van der Wall E.E., and Schalij M.J. Effect of radiofrequency catheter ablation for atrial fibrillation on left atrial cavity size. Am J Cardiol 97 (2006) 1220-1222
128. Mattioli A.V., Bonatti S., Monopoli D., Zennaro M., and Mattioli G. Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension. Blood Press 14 (2005) 273-278
129. Brooks W.W., Bing O.H., Robinson K.G., Slawsky M.T., Chaletsky D.M., and Conrad C.H. Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 96 (1997) 4002-4010
130. Brilla C.G., Funck R.C., and Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102 (2000) 1388-1393
131. Xu Z.G., Lanting L., Vaziri N.D., et al. Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade. Circulation 111 (2005) 1962-1969
132. Anand I.S., Latini R., Florea V.G., et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112 (2005) 1428-1434
133. Fliser D., Buchholz K., and Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110 (2004) 1103-1107
134. Ferrari R., Cicchitelli G., Merli E., Andreadou I., and Guardigli G. Metabolic modulation and optimization of energy consumption in heart failure. Med Clin North Am 87 (2003) 493-507
135. Wachtell K., Lehto M., Gerdts E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 (2005) 712-719
136. Pedersen O.D., Bagger H., Kober L., and Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100 (1999) 376-380
137. Vermes E., Tardif J.C., Bourassa M.G., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107 (2003) 2926-2931
138. Murray K.T., Rottman J.N., Arbogast P.G., et al. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm 1 (2004) 669-675
139. Ducharme A., Swedberg K., Pfeffer M.A., et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 152 (2006) 86-92
140. Maggioni A.P., Latini R., Carson P.E., et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149 (2005) 548-557
141. Madrid A.H., Bueno M.G., Rebollo J.M., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106 (2002) 331-336
142. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
143. The Captopril Prevention Project (CAPP) Study Group. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. Curr Hypertens Rep 1 (1999) 466-467
144. Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354 (1999) 1751-1756
145. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
146. Pizzetti F., Turazza F.M., Franzosi M.G., et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 86 (2001) 527-532
147. Torp-Pedersen C., and Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE study group. Trandolapril Cardiac Evaluation. Lancet 354 (1999) 9-12
148. Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45 (2005) 1832-1839
149. Boldt A., Wetzel U., Lauschke J., et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 90 (2004) 400-405
150. Jais P., Peng J.T., Shah D.C., et al. Left ventricular diastolic dysfunction in patients with so-called lone atrial fibrillation. J Cardiovasc Electrophysiol 11 (2000) 623-625
151. Boldt A., Scholl A., Garbade J., et al. ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol 101 (2006) 261-267
152. Farquharson C.A., and Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101 (2000) 594-597
153. Fraccarollo D., Galuppo P., Hildemann S., Christ M., Ertl G., and Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 42 (2003) 1666-1673
154. Zannad F., Alla F., Dousset B., Perez A., and Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized ALdactone Evaluation Study (RALES). RALES investigators. Circulation 102 (2000) 2700-2706
155. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
156. Liu J., Masurekar M.R., Vatner D.E., et al. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol 285 (2003) H2587-H2591
157. Palazzuoli A., Quatrini I., Vecchiato L., et al. Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure. J Cardiovasc Pharmacol 45 (2005) 563-568
158. Kobayashi M., Machida N., Mitsuishi M., and Yamane Y. Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure. Am J Hypertens 17 (2004) 1112-1119
159. Waagstein F., Stromblad O., Andersson B., et al. Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy. Eur J Heart Fail 5 (2003) 679-691
160. Kuhlkamp V., Schirdewan A., Stangl K., Homberg M., Ploch M., and Beck O.A. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 36 (2000) 139-146
161. Shiroshita-Takeshita A., Schram G., Lavoie J., and Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110 (2004) 2313-2319
162. Kumagai K., Nakashima H., and Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 62 (2004) 105-111
163. Siu C.-W., Lau C.-P., and Tse H.-F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 92 (2003) 1343-1345
164. Young-Xu Y., Jabbour S., Goldberg R., et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92 (2003) 1379-1383
165. Beukema W.P., Elvan A., Sie H.T., Misier A.R., and Wellens H.J. Successful radiofrequency ablation in patients with previous atrial fibrillation results in a significant decrease in left atrial size. Circulation 112 (2005) 2089-2095
166. Sanders P., Morton J.B., Kistler P.M., Vohra J.K., Kalman J.M., and Sparks P.B. Reversal of atrial mechanical dysfunction after cardioversion of atrial fibrillation: implications for the mechanisms of tachycardia-mediated atrial cardiomyopathy. Circulation 108 (2003) 1976-1984
167. Thomas L., Boyd A., Thomas S.P., Schiller N.B., and Ross D.L. Atrial structural remodelling and restoration of atrial contraction after linear ablation for atrial fibrillation. Eur Heart J 24 (2003) 1942-1951
168. Raitt M.H., Kusumoto W., Giraud G., and McAnulty J.H. Reversal of electrical remodeling after cardioversion of persistent atrial fibrillation. J Cardiovasc Electrophysiol 15 (2004) 507-512
169. Kinebuchi O., Mitamura H., Shiroshita-Takeshita A., et al. Temporal patterns of progression and regression of electrical and mechanical remodeling of the atrium. Int J Cardiol 98 (2005) 91-98
170. Albage A., Kenneback G., van der Linden J., and Berglund H. Improved neurohormonal markers of ventricular function after restoring sinus rhythm by the MAZE procedure. Ann Thorac Surg 75 (2003) 790-795
171. Lonnerholm S., Blomstrom P., Nilsson L., and Blomstrom-Lundqvist C. Atrial size and transport function after the MAZE III procedure for paroxysmal atrial fibrillation. Ann Thorac Surg 73 (2002) 107-111